Who are Peg-interferon alpha 2a and ribavin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Peg-IFN + RBV, C: Peg-interferon alpha-2a & Ribavirin, Pegasys /RBV, Peg-IFN + WB RBV for 16 weeks, Peg interferon + Ribavirin, Peg-IFN + LD RBV for 16 weeks.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/peg-interferon-alpha-2a-and-ribavin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Peg-interferon alpha 2a and ribavin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Peg-interferon alpha 2a and ribavin (Peg-interferon alpha 2a and ribavin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiviral combination therapy. Area: Virology/Hepatology.

phase 3 Antiviral combination therapy Interferon-alpha receptor; HCV RNA-dependent RNA polymerase Virology/Hepatology Small molecule Live · refreshed every 30 min

Target snapshot

Peg-interferon alpha 2a and ribavin (Peg-interferon alpha 2a and ribavin) — Hospices Civils de Lyon. Peg-interferon alpha-2a activates innate immune responses against viral infection, while ribavirin inhibits viral RNA synthesis, together targeting hepatitis C virus replication.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Peg-interferon alpha 2a and ribavin TARGET	Peg-interferon alpha 2a and ribavin	Hospices Civils de Lyon	phase 3	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-IFN + RBV	Peg-IFN + RBV	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
C: Peg-interferon alpha-2a & Ribavirin	C: Peg-interferon alpha-2a & Ribavirin	Kaohsiung Medical University Chung-Ho Memorial Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Pegasys /RBV	Pegasys /RBV	Beijing Kawin Technology Share-Holding Co., Ltd.	phase 3	Interferon alfa-2a (pegylated) + nucleoside analog combination	Interferon-alpha receptor; HCV RNA-dependent RNA polymerase
Peg-IFN + WB RBV for 16 weeks	Peg-IFN + WB RBV for 16 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon-alpha receptor; HCV RNA polymerase
Peg interferon + Ribavirin	Peg interferon + Ribavirin	University of Valencia	marketed	Antiviral combination therapy	Interferon-alpha receptor; Hepatitis C virus RNA-dependent RNA polymerase
Peg-IFN + LD RBV for 16 weeks	Peg-IFN + LD RBV for 16 weeks	National Taiwan University Hospital	marketed	Antiviral combination therapy	Interferon alpha receptor; HCV RNA polymerase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiviral combination therapy class)

Kaohsiung Medical University Chung-Ho Memorial Hospital · 6 drugs in this class
National Taiwan University Hospital · 6 drugs in this class
Casa Sollievo della Sofferenza IRCCS · 1 drug in this class
Hepatitis Resource Network · 1 drug in this class
Hospices Civils de Lyon · 1 drug in this class
MTI Medical Private Limited, Pakistan · 1 drug in this class
Pacific Health Foundation · 1 drug in this class
RedHill Biopharma Limited · 1 drug in this class
Sherief Abd-Elsalam · 1 drug in this class
The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Peg-interferon alpha 2a and ribavin — Competitive Intelligence Brief. https://druglandscape.com/ci/peg-interferon-alpha-2a-and-ribavin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing